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Edited by Judit Ova´diAbstract Ubiquitin (Ub) and the ubiquitin-like proteins (UBLs)
mediate an array of cellular functions. These proteins contain a
C-terminal glycine residue that is key to their function. Oxida-
tive conversion of C-terminal glycine-extended prohormones to
the corresponding a-amidated peptide is one step in the biosyn-
thesis of bioactive peptide hormones. The enzyme catalyzing
this reaction is peptidylglycine a-amidating monooxygenase
(PAM). We report herein that Ub is a PAM substrate with a
(V/K)amidation that is similar to other known peptide substrates.
This work is signiﬁcant because PAM and the UBLs co-localize
to the hypothalamus and the adrenal medulla and are both over-
expressed in glioblastomas.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ubiquitin modiﬁcation1. Introduction
Ubiquitin (Ub) is a small, highly conserved 76-residue poly-
peptide found in all eukaryotes [1]. Ub is the most studied and
best understood member of the family of Ub-related proteins,
compromised of the Type-1 ubiquitin-like proteins (UBLs) and
the Type-2 ubiquitin-domain proteins (UDPs) [2–4]. The post-
translational decoration of proteins with Ub or the UBLs
mediate an array of cellular functions, including directed pro-
tein degradation via the 26S proteasome [5], cell-cycle progres-
sion [6], apoptosis [7], regulation of gene expression and DNA
repair [7,8], and a sorting signal for vesicular or nuclear trans-
port [2,8]. The UDPs do not function by modifying other pro-
teins, but instead, contain an ubiquitin-like sequence within a
larger overall sequence that enables the UDP to bind to the
proteasome. The UDP is not degraded by the proteasome in*Corresponding author. Fax: +813 974 1733.
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doi:10.1016/j.febslet.2005.06.089the UDPÆproteasome complex, but instead seems to regulate
proteasomal function [4].
Critical to the cellular role played by Ub and the UBLs is a
conserved glycyl residue at the C-terminus (Table 1). The dec-
oration of proteins with Ub or the UBLs is accomplished by
the formation of an isopeptide bond between the C-terminal
glycine and the e-amide of Lys residue within the decorated
protein [2] or the formation of a standard peptide bond
between the C-terminal glycine and the N-terminus of the
ubiquitinated protein [14]. In addition to the attachment of a
single Ub or UBL to a protein, polyubiquitin chains can be
formed by the attachment of another Ub to Lys-48 of the at-
tached Ub [2]. Polyubiquitination targets the substrate protein
for destruction by the proteasome. Elimination of the C-termi-
nal glycine by proteolysis [15,16], site-directed mutagenesis
[12,13,17,18], or frame shift mutation [19] prevents Ub/UBL
function. These results indicate that any in vivo chemistry that
would eliminate the C-terminal glycine would compromise the
Ub/UBL system, mostly likely with deleterious health eﬀects
[5,12,13,19]. One known reaction that potentially could elimi-
nate the C-terminal glycine of Ub and the UBLs would be
C-terminal amidation: Ub1–75-CO-NH-CH2-COOHﬁ
Ub1–75-CO-NH2 + CHO-COOH. The non-functional product
with an amidated C-terminus, des-Gly-Ub1–75-amide in the
case of Ub, would be unable to form the critical linkage to
either the N-terminus or internal Lys residue of the acceptor
protein. In vivo, peptidylglycine a-amidating monooxygenase
(PAM, EC. 1.14.17.3) catalyzes the oxidative cleavage of glycyl
Ca–N bond in the glycine-extended neuropeptide precursors to
the a-amidated peptide and glyoxylate [20,21]. In addition,
PAM may also function in the biosynthesis of oleamide and
the other fatty acid primary amides via a similar cleavage of
long-chain N-acylglycine precursors [22,23]. In vitro studies
have demonstrated that PAM exhibits a broad substrate spec-
iﬁcity not only for glycine-extended peptides [24,25], but also
for an extensive set of non-peptide N-acylglycines and N-aryl-
glycines [22,25–27].
Because PAM and the UBLs co-localize to the hypothala-
mus [28,29] and the chromaﬃn granules of the adrenal medulla
[30–32] and are both over-expressed in glioblastomas [33,34],
we sought to determine if Ub and a number of glycine-
extended peptides based on theC-terminus ofUbwere amidated
by PAM. We report here that Ub and the Ub-derived peptides
are PAM substrates with V/K values that are comparable to
glycine-extended precursors of known a-amidated peptide
hormones. These data coupled with an earlier report of Ubblished by Elsevier B.V. All rights reserved.
Table 1
Comparison of the C-terminal sequences of Ub and UBLsa
Ub or UBL C-terminal 10 amino acidsb Ref.
Ubc LHLVLRLRGG [8]
SUMO-1 IEVYQEQTGG [8]
SUMO-2 IDVFQQQTGG [8]
SUMO-3 IDVFQQQTGG [8]
NEDD8 LHLVLALRGG [9]
ISG15 VFMNLRLRGG [10]
FAT10 LFLASYCIGG [11]
Ufm1 LRIIPRDRVG [12]
GATE16 VAYSGENTFG [13]
GABARAP VAYSDESVYG [13]
aThe sequences are all for the human proteins.
bUnderlined is the C-terminal glycine residue, a potential site of oxi-
dative cleavage to generate an a-amidated Ub/UBL derivative and
glyoxylate.
cHuman Ub and bovine Ub have the same amino-acid sequence [1].
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translational modiﬁcation of Ub and UBLs may represent an
unrecognized process to regulate the function of these proteins.
In addition, we ﬁnd that the V/K values for the Ub-derived
peptides do not correlate well with the value for Ub, bringing
into question the in vivo relevance of similar data generated
using small, model peptide substrates.2. Materials and methods
2.1. Materials
Bovine Ub, TPCK-treated trypsin, soybean trypsin inhibitor, Gly–
Gly, glycinamide, and N-acetylglycine were from Sigma, 2-(1-H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate
(HBTU) and 1-hydroxybenzotriazole (HOBt) were from Anaspec, N-
dansyl-Tyr-Val-Gly and 4-(dimethylamino)azobenzene-4 0-sulfonyl
chloride (dabsyl chloride) were from Fluka BioChemika, bovine cata-
lase was from Worthington, diisopropylethylamine (DIPEA) was from
Advanced Chemtech, and Arg–Gly–Gly was from Research Plus, Inc.
PAM was gift from Unigene Laboratories, Inc. Pyruvate-extended N-
acetylphenylalanine (N-Ac-Phe-pyruvate, 2,4-diketo-5-acetamido-6-
phenylhexanoic acid) was synthesized using a published procedure
[36]. All other reagents were of the highest quality available from com-
mercial suppliers.
2.2. PAM-catalyzed consumption of O2 and the production of glyoxylate
from ubiquitin
Reactions at 37 ± 0.1 C were initiated by the addition of rat PAM
(39 lg) into 4.0 mL of 100 mM MES/NaOH, pH 6.0, 30 mM NaCl,
1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 lM Cu(NO3)2,
10 lg/mL catalase, 5.0 mM ascorbate, 500 lM ubiquitin (4.25 mg/
mL), and either 0 or 45 lM N-Ac-Phe-pyruvate. N-Ac-Phe-pyruvate
inhibits the PAL activity of bifunctional PAM with a Ki = 0.24 lM
and also weakly inhibits the peptidylglycine a-hydroxylating monoox-
ygenase (PHM) activity with a Ki P 25 lM [36]. In one sample, O2
consumption was continuously monitored using a Yellow Springs
Instrument Model 53 oxygen monitor. In a second matched sample,
aliquots were removed at the indicated time and added to a vial con-
taining one-ﬁfth volume of 6% (v/v) TFA to quench the reaction.
The concentration of glyoxylate in each quenched sample was deter-
mined spectrophotometrically using the method of Christmen et al.
[37] as modiﬁed by Katopodis and May [26].
2.3. Tryptic digestion of ubiquitin followed by HPLC analysis of the
dabsylated reaction products
Ub (4.25 mg in 1.0 mL) was incubated with 43 lg of PAM in
100 mM MES/NaOH, pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol,
0.001% (v/v) Triton X-100, 1.0 lM Cu(NO3)2, 10 lg/mL catalase,
and 5.0 mM ascorbate. The control consisted of the same reaction con-ditions without the addition of PAM. After 1.0 h at 37 ± 0.1 C, the
reactions were terminated by the 0.2 mL of 6% (v/v) TFA and the vol-
umes reduced to 0.3 mL by ultraﬁtration. Three changes of 1.0 mL of
25 mM NaHCO3 was suﬃcient to adjust the pH of the solutions to
8.2–8.5. Trypsin (0.1 mg) was added to the solutions, the solution incu-
bated for 30 min at 37 ± 0.1 C, and proteolysis terminated by the
addition of 0.2 mg soybean trypsin inhibitor. Our procedure is based
on the trypsinization procedures of Wilkinson and Audhya [38]. The
resulting solution was diaﬁltered using a Centricon-C3 diaﬁlter and
the ﬂowthrough containing the released Gly–Gly dipeptide and glycin-
amide were dabsylated as described by Stocchi et al. [39]. The dabsy-
lation reaction mixture was analyzed by RP-HLC using a Keystone
Scientiﬁc Hypersil ODS column (4.6 · 100 mm). Separations were per-
formed at 32 C using a binary solvent system of 25 mM potassium
phosphate, pH 6.8 (solvent A) and acetonitrile (solvent B) as follows:
A/B of 80/20 for 0–10 min, A/B of 70/30 for 10–20 min, and A/B of 30/
70 for 20–30 min. Analytes were detected at 436 nm using a ﬂow-
through UV/visible variable wavelength detector. Under these condi-
tions, dabsyl-Cl had a retention time 8.0 min, glycine of 14.6 min,
Gly–Gly of 15.7 min, and glycinamide of 22.7 min.
2.4. Initial rate studies of RGG (Ub74–76) amidation
Reactions at 37 ± 0.1 C were initiated by the addition of PAM
(26 lg) into 3.0 mL of 100 mM MES/NaOH, pH 6.0, 30 mM NaCl,
1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 lM Cu(NO3)2,
10 lg/mL catalase, 5.0 mM ascorbate, and 0.5–8.0 mM RGG. Initial
rates of O2 consumption were measured using an O2 electrode. VMAX
values were normalized to controls performed at 11.0 mM N-acetylgly-
cine. Under these conditions, the initial concentration of O2 was
217 lM [40].
2.5. Inhibition of N-dansyl-tyr-val-gly amidation
Reactions at 37 ± 0.1 C were initiated by the addition of PAM (30–
40 ng) into 0.25 mL of 100 mM MES/NaOH, pH 6.0, 30 mM NaCl,
1.0% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 lM Cu(NO3)2,
10 lg/mL catalase, 6.0 mM ascorbate, 8.0 lM N-dansyl-Tyr-Val-Gly,
and either Ub or the Ub-derived peptides (concentration
range = 1.0–3.0 · KM). The reaction was terminated at the desired time
interval by removing a 40 lL aliquot of the reaction and adding this to
a HPLC microvial containing 8 lL of 6% (v/v) TFA. Amidation of N-
dansyl-Tyr-Val-Gly was then monitored by reverse-phase HPLC [41].
Under these conditions, the KM for N-dansyl-Tyr-Val-Gly is 3.5 lM.
2.6. The VMAX values for the amidation of Ub and the Ub-derived
peptides
The quantities of Ub and the Ub-derived peptides required to deﬁne
the VMAX values at peptide concentration (P 10 · KM) were prohibi-
tively expensive. Measurements of the VMAX values were obtained by
determining the initial rates of O2 consumption or glyoxylate produc-
tion at one peptide concentration and then using the initial rate to cal-
culate the VMAX value from the Michealis–Menton expression.
For Ub, O2 consumption was monitored using an O2 electrode fol-
lowing the addition of 100 lg of PAM into 1.6 mL of 100 mM MES/
NaOH, pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Triton
X-100, 1.0 lM Cu(NO3)2, 10 lg/mL catalase, 5.0 mM ascorbate, and
0.87 mM Ub. The initial rates obtained at 0.87 mM Ub were normal-
ized to values obtained for 11 mM N-acetylglycine.
For N-Ac-RGG (N-Ac-Ub74–76), N-Ac-LRGG (N-Ac-Ub73–76),
N-Ac-LRLRGG (N-Ac-Ub71–76), N-Ac-LHLVLRLRGG (N-Ac-
Ub67–76), and N-Ac-QKESTLHLVLRLRGG (N-Ac-Ub62P–76), gly-
oxylate production was initiated by the addition of 36 lg of PAM into
0.9 mL of 100 mMMES/NaOH, pH 6.0, 30 mM NaCl, 1.0% (v/v) eth-
anol, 0.001% (v/v) Triton X-100, 1.0 lMCu(NO3)2, 10 lg/mL catalase,
5.0 mM ascorbate, and 1.0 mM peptide. At the desired times, a 75-lL
aliquot was removed and added to a vial containing 15 lL of 6% (v/v)
TFA to terminate the reaction. The concentration of glyoxylate pro-
duced in the acidiﬁed samples was determined spectrophotometrically.
The initial rates of glyoxylate production from the Ub-derived peptides
were normalized to values obtained for 1.0 mM N-acetylglycine.
2.7. Data analysis
Kinetic parameters for RGG were obtained by a KaleidaGraphTM
ﬁt of the initial velocity (v) vs. [RGG] ([S]) data to
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Fig. 1. The reaction catalyzed by bifunctional PAM. PAM is composed of two catalytic entities. PHM catalyzes the hydroxylation of the a-carbon of
the glycyl radical and PAL catalyzes the dealkylation of the carbinolamide to the amide product and glyoxylate.
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where KM is the apparent Michaelis constant for RGG at ﬁxed [ascor-
bate] and [O2] concentrations and VMAX is the apparent maximum ini-
tial velocity at saturating [RGG].
Values for Ki were obtained from obtained by a KaleidaGraph
TM ﬁt
of the initial velocity (v) vs. [inhibitor] ([I]) at constant [N-dansyl-Tyr-
Val-Gly] ([DNS-YVG]) to:
v ¼ V MAX½DNS-YVG
KMð1þ ½I=KiÞ þ ½DNSYVG ð2Þ
When the inhibitor is a non-ﬂuorescent alternative substrate, the Ki va-
lue equals the apparent KM for that substrate at ﬁxed [ascorbate] and
[O2] [42].
The apparent KM values were then used to estimate the apparent
VMAX values for Ub and the Ub-derived peptides (other than RGG)
by measuring the initial velocity, v, at one substrate concentration,
[S], and then solving for VMAX in Eq. (1).
2.8. Peptide synthesis
All peptides were synthesized on single substituted wang resins
(AnaSpec or Advanced Chemtech) using an Advanced Chemtech Apex
396 DC automated peptide synthesizer with standard 9-fuorenylmeth-
oxycarbonyl (FMOC) and tert-butyl protection scheme [43]. FMOC
was removed with 25% piperidine (Lancaster) in dimethylformamide
(v/v) solution (DMF). All couplings were carried out with a 5 equiva-
lents excess to the resin capacity. Couplings were achieved by the addi-
tion of FMOC amino acid, HBTU, HOBt, and DIPEA in a ratio of
1:1:1:2 followed by vortex mixing for 1 h. Cleavage of the peptides
was achieved in 1.5 mL of TFA:triisopropyl silane:water (95:3:2) per
100 mg of resin. Peptides were collected with cold diethyl ether precip-
itation followed by centrifugation and three washes of diethyl ether.
Puriﬁcation was performed via reverse-phase HPLC puriﬁcation on
a Waters Prep LC 4000 with gradient elution using water (0.1%
TFA) and acetonitrile (0.1% TFA) on a Waters 25 mm module C18 col-
umn and a Waters 2487 Dual k absorbance detector (210 and 254 nm).
Lyophilized peptide powders were obtained with a Labconco Freezez-
one 4.5. Either matrix-assisted laser desorption ionization mass spec-
trometry with time of ﬂight detector or electrospray ionization mass
spectrometry and amino-acid analysis were used to conﬁrm the singly
protonated peptide identities. Lyophilized peptides were stored at
40 C. Physical characterization: N-Ac-RGG (RT 9.63 min; m/
z(pred) 331.35, m/z(obsv) 330.99; N-Ac-LRGG (RT 19.40 min;
m/z(pred) 444.51, m/z(obsv) 444.19; N-Ac-LRLRGG (RT 25.3 min;
m/z(pred) 713.86, m/z(obsv) 713.19; N-Ac-LHLVLRLRGG (RT
35.28 min; m/z(pred) 1176.46, m/z(obsv) 1175.61; N-Ac-
QKESTLHLVLRLRGG (RT 31.17 min; m/z(pred) 1750.06, m/z(obsv)
1749.05.0 5 10 15 20
Time (minutes)
Fig. 2. The PAM-catalyzed consumption of O2 and the production of
glyoxylate from Ub. Reactions at 37 C with or without N-Ac-Phe-
pyruvate were initiated by the addition of PAM as described in Section
2. In one sample, O2 consumption was measured with an O2 electrode,
the solid line (——) representing the reaction in the absence of N-Ac-
Phe-pyruvate and the dashed line (- - -) representing the sample
containing 45 lM N-Ac-Phe-pyruvate. In a second matched sample,
aliquots were removed, the reactions terminated with acid, and then
assayed for glyoxylate production. The open circles (s) are from the
sample without added N-Ac-Phe-pyruvate and the closed circles (d)
are from the sample containing 45 lM N-Ac-Phe-pyruvate.3. Results and discussion
3.1. The PAM-dependent consumption of oxygen and the
formation of glyoxylate from ubiquitin
Peptide amidation, as catalyzed by PAM, occurs in two
steps. The ﬁrst step is the copper-, ascorbate, and O2-depen-
dent hydroxylation of the a-carbon of the C-terminal glycine
[44] and the second step is the zinc-dependent conversion of
the a-hydroxyglycine-extended peptide to the a-amidatedpeptide and glyoxylate [45,46]. Each step in the amidation
reaction is catalyzed at separate active sites, either as individ-
ual monofunctional proteins PHM and peptidylamidoglyco-
late lyase (PAL) or as separate domains in bifunctional
PAM (Fig. 1). Bifunctional PAM exhibits both PHM and
PAL activities that are proteolytically separable in vitro [47]
and in vivo [48].
Shown in Fig. 2 is the PAM-dependent consumption of O2
and production of glyoxylate from 500 lM bovine Ub. These
data strongly suggest that Ub is ﬁrst converted to the
a-hydroxyglycine-extended intermediate by the PHM active
site of bifunctional PAM and is subsequently dealkylated to
Ub1–75-NH2 and glyoxylate at the PAL active site. The pro-
duction of glyoxylate lags behind the consumption of O2 for
Ub, leading to an accumulation of the a-hydroxyglycine inter-
mediate to concentrations as high as 50 lM. Signiﬁcant con-
centrations a-hydroxyglycine intermediate, representing
30–50% of the total peptide concentration, were also found
during the PAM-catalyzed amidation of N-dansyl-Tyr-Val-
Gly [49] and [Ala15]-GRF(1-29)-Gly [50]. The presence of the
a-hydroxyglycine intermediate, in the steady-state, during the
amidation of Ub, N-dansyl-Tyr-Val-Gly and [Ala15]-GRF
(1-29)-Gly at concentrations in great excess over the enzyme
concentration argues against any signiﬁcant channeling of
Fig. 3. Reverse-phase HPLC analysis of the dabsylated products
obtained following the tryptic digestion of Ub before and after PAM
treatment. Ub and PAM-treated Ub were trypsinized following the
literature protocols [38]. The small peptide fragments were separated
from larger products and unreacted Ub (or PAM-modiﬁed Ub) by
ultraﬁltration and dabsylated. Reverse-phase HPLC analysis of the
dabsylated, trypsin-generated products from untreated Ub is shown in
panel A and that for PAM-treated Ub is in panel B. Under the HPLC
separation conditions, the retention times were as follows: dabsyl-
Cl = 8.0 min, dabsylated glycine = 14.6 min, dabsylated Gly–Gly =
15.7 min, and dabsylated glycinamide = 22.7 min.
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bifunctional PAM, in agreement with previous results [51].
Mounier et al. [36] has reported that N-Ac-Phe-pyruvate
inhibits PAL with a Ki value of 0.24 lM and also weakly inhib-
its PHM with Ki values of 50–100 lM (competitive vs. ascor-
bate and uncompetitive vs. the peptide substrate). Consistent
with this report, we ﬁnd that the addition of 45 lM N-Ac-
Phe-pyruvate has only a small eﬀect on the initial rate of O2
consumption in the presence of PAM and Ub (dashed line in
Fig. 2), but decreases the production of glyoxylate by 97%
(solid circles in Fig. 2). This experiment provides additional
evidence for the initial formation of Ub1–75-a-hydroxyglycine
during the PAM-catalyzed amidation of Ub.
3.2. The PAM-dependent production of a-amidated ubiquitin,
Ub1–75-CO-NH2
The consumption of O2 and the production of glyoxylate
upon the addition of PAM to Ub are strong indications of pep-
tide amidation; however, these data do not provide direct
evidence for the formation of the a-amidated product,
Ub1–75-CO-NH2. Ub is a stable protein that is remarkably
resistant to denaturation by pH and heat [52]. The X-ray
[53] and NMR [54] structures of Ub reveal a well-deﬁned, N-
terminal hydrophobic core of 71 amino acids and a C-termi-
nal, solvent-exposed projection of 5 amino acids out from
the core. Tryptic digestion in the absence of protein denatur-
ants only cleaves the Arg74–Gly75 bond yielding inactive
Ub1–74 and the Gly75–Gly76 dipeptide [38]. In contrast, tryptic
digestion of the PAM-generated Ub1–75-CO-NH2 would gener-
ate glycinamide, H2N-CH2-CO-NH2, in place of the Gly–Gly
dipeptide.
Samples of Ub and PAM-treated Ub were trypsinized
according to Wilkinson and Audhya [38] and the resulting
solutions diaﬁltered to remove PAM and any undigested pro-
tein. The ﬁltrates were dabsylated and the mixtures analyzed
for Gly–Gly or glycinamide formation by reverse phase
HPLC. In the control experiment starting with Ub, we identi-
ﬁed Gly–Gly (Fig. 3A) while glycinamide was produced from
the PAM-treated Ub (Fig. 3B). This result indicates that a-
amidated Ub1–75-CO-NH2 is one product of the treatment of
Ub with PAM.
3.3. Steady-state kinetic analysis of the amidation of Ub and the
C-terminal Ub-derived peptides
Using a set of peptides of the form N-dansyl-(Gly)4-X-Gly in
which the amino acid at position ‘‘X’’ was substituted with the
20 amino acids typically found in proteins, Tamburini et al. [24]
reported that the penultimate amino acid dramatically aﬀected
the V/K for the amidation of glycine-extended peptides. For
example, the (V/K)amidation of N-dansyl-(Gly)4-Glu-Gly was
1250-fold lower than that of N-dansyl-(Gly)4-Phe-Gly
4
and the amidation of N-dansyl-(Gly)4-Gly-Gly and N-
dansyl-(Gly)4-Asp-Gly was barely detectable. The data from
Tamburini et al. [24] are consistent with other PAM substrate
speciﬁcity studies employing smaller sets of model peptide sub-
strates [55–57]. The model studies are diﬃcult to reconcile with
the known occurrence of a-amidated peptides. The precursor
for joining peptide with a C-terminal Glu-Gly sequence is ami-4 N-Dansyl-(Gly)4-Phe-Gly was the peptide with the highest V/K in the
work of Tamburini et al. [24].dated by extracts of mouse AtT-20 cells [58] and each of the 20
common amino acids has been found as a C-terminal amino-
acid amide in a bioactive peptide, including glycinamide and
aspartamide [20,59]. One possible explanation could be that
the reaction conditions within the secretory vesicles diﬀer from
those used to generate the in vitro data. Mains et al. [60] point
out that the concentrations of PAM (P 3 lM) and total gly-
cine-extended peptides (10 mM) are higher within the secre-
tory granules than those used for the in vitro evaluation of
steady-state kinetic parameters. Another possibility could be
that the relatively small, model substrates do not fully access
the range of binding interactions that are likely to exist between
larger substrates and the PHM active site. This is reasonable gi-
ven that the PHM active site is located within two hinged, clam-
shell-like domains of about 150 amino acid residues. The
domains are about 8 A˚ apart with hydrophobic faces of
500 A˚2 [61].
Table 2
Steady-state kinetic constants for Ub and glycine-extended peptides derived from the C-terminus of Uba
Substrate Sequence KM or Ki (lM) VMAX (lmol/min/mg) Relative V/K
D-Tyr-Val-Glyb D-YVG KM = 220 ± 31 7.9 ± 0.78 17
Ub1–76 see Ref. [1] KM = 600 ± 65 1.3 1
Ub74–76 RGG KM = 2500 ± 290 3.4 ± 0.16 0.6
Ki = 1500 ± 160
N-Acetyl-Ub74–76 N-Ac-RGG Ki = 120 ± 10 0.5 2
N-Acetyl-Ub73–76 N-Ac-LRGG Ki = 130 ± 25 0.4 1
N-Acetyl-Ub71–76 N-Ac-LRLRGG Ki = 24 ± 2.2 1.5 30
N-Acetyl-Ub67–76 N-Ac-LHLVLRLRGG Ki = 18 ± 4.0 0.3 8
N-Acetyl-Ub62–76 N-Ac-QKESTLHLVLRLRGG Ki = 20 ± 2.1 0.4 9
aKM, VMAX, and V/K values are all apparent constants determined measured by varying the indicated glycine-extended peptide substrate at ﬁxed
initial concentrations of O2 (217 lM) [40] and ascorbate (5.0 mM).
bThe Ki values are also apparent constants obtained by measuring the inhibition of N-dansyl-Tyr-Val-NH2 formation at ﬁxed initial concentrations
of 217 lM O2, 6.0 mM ascorbate, and 8.0 lM N-dansyl-Tyr-Val-Gly. The Ki value ascertained in this way should equal the KM [42]; the Ki for
Ub74–76 being in reasonable agreement with the KM.
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between full-length Ub and shorter glycine-extended peptides
based on the ubiquitin C-terminus (Table 2). The kinetic con-
stants for D-Tyr-Val-Gly, a model substrate used in many
PAM/PHM studies, is included as reference for the data on
Ub and the Ub-derived peptides. N-Dansyl-(Gly)4-Val-Gly
ranks ﬁfth on the Tamburini scale with a V/K that is 8% of
the value for N-dansyl-(Gly)4-Phe-Gly and is >100-fold higher
than the V/K for N-dansyl-(Gly)4-Gly-Gly amidation [24].
All of the Gly–Gly-extended peptides exhibited higher V/K
values than expected based the results for N-dansyl-(Gly)4-
Gly-Gly. We ﬁnd a 50-fold variation in the V/K for Ub
and the Ub-derived peptides with the lowest value measured
for Arg–Gly–Gly and the highest value measured for N-Ac-
Ub71–76 (Table 2). The V/K values for N-Ac-Ub71–76, N-Ac-
Ub67–76, and N-Ac-Ub62–76 are greater than the value obtained
for Ub and are approximately equal to the value for D-Tyr-
Val-Gly. The variation in the V/K value is largely a KM eﬀect
because the KM values vary 130-fold while the VMAX values
vary only 30-fold. The data of Table 2 are consistent with
our hypothesis that active site contacts with substrate amino
acids farther removed from the C-terminal glycine than the
penultimate amino acid have an eﬀect on the ‘‘amidability’’
of the peptide substrate.
Unfortunately, the conclusions we can draw from the
steady-state kinetic data of Table 2 is restricted by the VMAX
values obtained. The limited availability of Ub and the Ub-
derived precluded a better determination of the VMAX values
for these peptides. However, the non-ﬂuorescent substrates like
Ub and the Ub-derived peptides can be treated as competitive
inhibitors of N-dansyl-Tyr-Val-Gly amidation because their
binding to PHM/PAMwill prevent the formation of the ﬂuores-
cent product, N-dansyl-Tyr-Val-NH2. The Ki,s value obtained
from these experiments is equal to the KM for the non-ﬂuores-
cent peptide substrate [22,42]. These experiments enable an
accurate determination of the KM values for non-ﬂuorescent
substrates that exhibit relatively lowVMAXvalues and are of lim-
ited availability – exactly the case for Ub and the Ub-derived
peptides.4. Conclusion
We show here, for the ﬁrst time, that Ub is a substrate for
peptidylglycine a-amidating monooxygenase being convertedto des-Gly-Ub1–75-amide and glyoxylate. Like other PAM sub-
strates, the amidation of Ub most likely proceeds by the initial
hydroxylation of the C-terminal glycine followed by the deal-
kylation of the carbinolamide intermediate to generate the
a-amidated product.
The amidated Ub derivative, lacking the C-terminal glycyl
residue, will not function normally as this post-translational
modiﬁcation would prevent protein ubiquitination. Our dis-
covery of this chemistry may be of biological signiﬁcance given
that PAM and the UBLs co-localize to the hypothalamus
[28,29] and the chromaﬃn granules of the adrenal medulla
[30–32] and are both over-expressed in glioblastomas [33,34].
Furthermore, the post-translational modiﬁcation of Ub or
the UBLs by amidation or glutathionylation [35] may repre-
sent an unrecognized method to regulate Ub/UBL function
in vivo. One interesting future study would be to immunopre-
cipitate ubiquitin from the cells listed above that co-express Ub
and PAM and determine if any Ub1–75-CO-NH2 has been pro-
duced, after separation of the Ub/Ub1–75-CO-NH2 from the
antibody under denaturing conditions. The presence of the
Ub1–75-CO-NH2 could be determined by mass spectrometry
or perhaps the Tatemoto and Mutt procedure for the identiﬁ-
cation of a-amidated peptides [62]. If Ub1–75-CO-NH2 is iden-
tiﬁed in cells that can be or are grown in culture, growth of the
Ub1–75-CO-NH2-producing cells in the presence of a PAM
inhibitor should then decrease the amount of Ub1–75-CO-
NH2 found [23].
The V/K values obtained for the amidation of Ub and pep-
tides derived from the C-terminus of Ub are higher than
expected based on the structure–activity relationships (SARs)
generated using tripeptide and hexapeptide substrates. Our data
indicate that these relatively short model substrates cannot mi-
mic that full range of enzyme–substrate contacts that exist in the
PHM/PAM active site for longer peptide substrates. In vivo,
PAM substrates exhibit a tremendous range, from 4 amino
acids for the glycine-extended TRH pecursor [63] to 154 amino
acids for the sorbin precursor [64]. Our data may, at least, par-
tially explain why the current PAM SAR data does not ade-
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